Literature DB >> 22126574

FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia.

Ekchol Mukda1, Katsarin Pintaraks, Rachchadol Sawangpanich, Surapon Wiangnon, Samart Pakakasama.   

Abstract

Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human hematologic malignancies. Mutations in fms-like tyrosine kinase 3 (FLT3) gene including internal tandem duplication (ITD) and point mutation in the tyrosine kinase domain (TKD) as well as in nucleoplasmin (NPM1) gene are associated with pathogenesis of acute myeloblastic leukemia (AML). Several reports have demonstrated high incidences of the FLT3 and NPM1 mutations in adult AML patients. Since the pathogenesis of pediatric AML is different from that of adult and the FLT3 and NPM1 mutations have not been well characterized in childhood AML. Therefore, the objective of this study was to determine the frequencies of FLT3 and NPM1 mutations in 64 newly diagnosed childhood AML patients. All blood and bone marrow samples were previously diagnosed with AML by using flow cytometry and/or cytochemistry. FLT3-ITD and FLT3-TKD were detected by PCR and PCR-RFLP methods, respectively. The NPM1 mutation was analyzed by PCR and direct DNA sequencing. The FLT3 mutations were detected in 7 of 64 (11.1%), including FLT3-ITD in 4 of 64 (6.3%) and FLT-TKD in 3 of 62 (4.8%). The NPM1 mutation was not detected in this cohort. By multivariate analysis, white blood cell counts, peripheral blood and bone marrow blast cell counts at diagnosis were significantly higher in children with FLT3-ITD (P<0.05). In addition, the median percentage of CD117 was significantly higher in leukemic blast cells with FLT3-ITD than those with wild type (P=0.01). We did not find any FLT3 mutations in children aged less than 5 years. The AML M3 cell type was most frequently associated with FLT3 gene mutations (50%). In conclusion, the FLT3 mutations was found in 11.1% but none of NPM1 mutation was detected in Thai children with AML. These data support the hypothesis of different biology and pathogenesis between adult and childhood AML.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22126574

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

Authors:  Patricia Rubio; B Campos; J A Digiorge; M S Gallego; A Medina; J G Rossi; M S Felice; C N Alonso
Journal:  Int J Hematol       Date:  2016-07-19       Impact factor: 2.490

Review 2.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

3.  Accumulation of FLT3(+) CD11c (+) dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor.

Authors:  Heng-Xiu Yan; Wei-Wei Li; Yan Zhang; Xia-Wei Wei; Li-Xin Fu; Guo-Bo Shen; Tao Yin; Xiu-Ying Li; Hua-Shan Shi; Yang Wan; Qing-Yin Zhang; Jiong Li; Sheng-Yong Yang; Yu-Quan Wei
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

4.  FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India.

Authors:  Suchitra Swaminathan; Swati Garg; Manisha Madkaikar; Maya Gupta; Farah Jijina; Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2014-04

5.  Down-Regulation of Ribosomal S6 kinase RPS6KA6 in Acute Myeloid Leukemia Patients.

Authors:  Mohammad Rafiee; Mohammad Reza Keramati; Hosein Ayatollahi; Mohammad Hadi Sadeghian; Mohieddin Barzegar; Ali Asgharzadeh; Mohsen Alinejad
Journal:  Cell J       Date:  2016-05-30       Impact factor: 2.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.